BCAB.US Bioatla Inc

Healthcare Biotechnology USA Stocks
1.55 USD
Close of Nov 14, 2026
1.07 71.50
Market cap
USD 2.59M
P/E
-
P/B
2.68x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BCAB.US undervalued?

Graham number

The Graham number of Bioatla Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bioatla Inc fundamental analysis

No fundamental analysis for Bioatla Inc yet.

Bioatla Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bioatla Inc

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal …

Full company profile